Company news

Amplia Therapeutics Ltd. news in 2020

Amplia Therapeutics Ltd.'s news releases, calls and decks from 2020, newest first.

View company

Amplia Receives $0.53m R&D Tax Incentive

December 1, 2020

Appendix 4D and Financial Report Half Year Ended 30 Sep 2020

November 27, 2020

ATX - Sep 2020 Quarter Activities and Cashflow Reports

October 28, 2020

Response to ASX Price Query

October 20, 2020

First Human Dose in Phase 1 Clinical Trial of AMP945

October 8, 2020

Amplia Receives Ethics Clearance fo Conduct Phase 1 Trial

September 7, 2020

Quarterly Activities and Cashflow Reports - June 2020

July 26, 2020

Nucleus Network Appointed to Conduct Phase 1 Clinical Trial

July 22, 2020

Institutional Entitlement Offer Completed

July 2, 2020

Capital Raising - Investor Presentation

July 1, 2020

Entitlement Offer to Fund Phase 1 Clinical Trial

June 30, 2020

Preliminary Toxicology Studies Support Phase1 Clinical Trial

June 30, 2020

Preliminary Final Report - YE 31 March 2020

May 29, 2020

FDA Orphan Drug Designation - Idiopathic Pulmonary Fibrosis

May 19, 2020

Quarterly Activities Report - March 2020 Qtr

April 27, 2020

App 4C - Quarterly Cash Flow Report - March 2020 Qtr

April 27, 2020

FDA Awards Orphan Drug Designation for Pancreatic Cancer

March 24, 2020

Dr. John Lambert appointed as Managing Director

February 6, 2020

Appendix 4C Cash Flow - Dec 2019 Qtr

January 29, 2020

Amplia Therapeutics Undertakes Placement

January 19, 2020

Decks in 2020